NeuroPace Inc
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the quarter ended September 30, 2025, our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act)adopted, modified orterminated the contracts, instructions, or written plans for the purchase or sale of our securities set forth in the table below:
| Name and Position | Action | Adoption/Termination Date | Type of Trading Arrangement: Rule 10b5-1(1) | Total Shares of Common Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|
| Martha Morrell, Chief Medical Officer | Adoption | September 15, 2025 | X | 91,669(2) | December 31, 2026 |
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) Including the exercise and sale of up to 34,219 shares of the Company’s common stock subject to stock options.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.